Document is current
Any future updates will be listed below
-
Authors
Ferretti, Giulia D. S.
Quaas, Colleen E.
Bertolini, Irene
Zuccotti, Alessandro https://orcid.org/0000-0001-5581-7980
Saatci, Ozge https://orcid.org/0000-0002-0124-044X
Kashatus, Jennifer A.
Sharmin, Salma
Lu, David Y.
Poli, Adi Narayana Reddy
Quesnelle, Abigail F. https://orcid.org/0009-0009-2818-0326
Rodriguez-Blanco, Jezabel
de Cubas, Aguirre A.
Hobbs, G. Aaron
Liu, Qin
O’Bryan, John P. https://orcid.org/0000-0001-5386-1080
Salvino, Joseph M.
Kashatus, David F. https://orcid.org/0000-0001-8007-0612
Sahin, Ozgur
Barnoud, Thibaut https://orcid.org/0000-0001-5588-6281
- License Information
-
More Information
Article History
Received: 13 October 2023
Revised: 29 April 2024
Accepted: 1 May 2024
First Online: 28 May 2024
Competing interests
: JMS owns equity in Alliance Discovery, Inc., Barer Institute, Context Therapeutics, and consults for Syndeavor Therapeutics. OS is the co-founder of OncoCube Therapeutics LLC, and the founder and president of LoxiGen, Inc. All other authors have no competing interests.
: No human subjects were used in this study. All animal studies were carried out in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the NIH. All protocols were approved by the Medical University of South Carolina (MUSC) Institutional Animal Care and Use Committee (IACUC).
